Tellgen Corporation (SHE:300642)

China flag China · Delayed Price · Currency is CNY
17.90
+0.38 (2.17%)
Mar 10, 2026, 1:25 PM CST
Market Cap2.80B +16.8%
Revenue (ttm)373.48M -19.3%
Net Income15.92M -77.5%
EPS0.10 -77.5%
Shares Out159.86M
PE Ratio178.40
Forward PEn/a
Dividend0.15 (0.86%)
Ex-Dividend DateMay 20, 2025
Volume1,644,760
Average Volume2,912,905
Open17.25
Previous Close17.52
Day's Range17.25 - 17.97
52-Week Range11.51 - 32.80
Beta0.44
RSI39.35
Earnings DateApr 25, 2026

About Tellgen

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China. [Read more]

Sector Healthcare
Founded 2003
Employees 522
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300642
Full Company Profile

Financial Performance

In 2024, Tellgen's revenue was 436.78 million, a decrease of -19.53% compared to the previous year's 542.81 million. Earnings were 34.53 million, a decrease of -61.37%.

Financial Statements